A pancreatic metastasis from a colon carcinoma mimicking a primary tumor diagnosed by EUS-guided fine-needle biopsy

Rizza, Stefano; Maldi, Elena; Laudi, C.; Mellano, Alfredo; Pisacane, Alberto; Staiano, Teresa

doi:10.4103/eus-d-21-00186

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 90% of pancreatic cancers harbor oncogenic KRAS mutations (16,17). With the improvement in many advanced medical diagnostic technologies, such as endoscopic ultrasound, the early diagnosis rate of PAAD has been greatly improved (18)(19)(20). However, given the limited effectiveness of current treatments for PAAD, new promising biomarkers are urgently needed to improve the prognosis and treatment of PAAD.…”

Section: Introductionmentioning

confidence: 99%

CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma

Liu,

Li,

Han

2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundPancreatic adenocarcinoma (PAAD) is characterized by lower immunogenicity with a poor response rate to immune checkpoint inhibitors (ICIs) and exhibits the poorest prognosis of all solid tumors, which results in the highest tumor-related mortality among malignancies. However, the underlying mechanisms are poorly understood. In addition, diverse carbohydrate sulfotransferases (CHSTs), which are involved in the sulfation process of these structures, play an important role in the metastatic spread of tumor cells. Aberrant glycosylation is beginning to emerge as an influencing factor in tumor immunity and immunotherapy. Therefore, it might serve as a biomarker of the immunotherapeutic response in tumors. The purpose of the study was to evaluate the role of CHST12 in PAAD prognosis and its relevance to the immunotherapeutic response.MethodsA comprehensive investigation of the interactions between CHST12 expression and the immune microenvironment as well as the clinical significance of CHST12 in PAAD was conducted. Data derived from the Cancer Genome Atlas (TCGA) database were analyzed using univariate and multivariate approaches, the Tumor Immune Estimation Resource (TIMER), and Tumor Immune Dysfunction and Exclusion (TIDE) algorithms. Publicly available datasets were analyzed in this study. These data can be found on websites such as http://www.xiantao.love and https://www.proteinatlas.org. An assessment of the predictive value of CHST12 for PAAD prognosis was conducted using univariate and multivariate Cox regression analysis, Kaplan–Meier analysis, and nomograms. The TIMER algorithm calculates the proportions of six types of immune cells. The TIDE algorithm was used to indicate the characteristics of tumors that respond to ICI therapy.ResultsThe mRNA and protein levels of CHST12 showed the opposite trend. CHST12 mRNA expression was significantly upregulated in PAAD. According to Cox regression analysis, CHST12 RNA expression acts as a protective factor for overall survival [hazard ratio (HR), 0.617, P < 0.04]. Functional annotation indicated that CHST12-associated differentially expressed genes (DEGs) were related to the signaling activity of receptor tyrosine kinases and the regulation of ubiquitin-protein transferase. These are usually involved in tumor development and may be related to the treatment responses of immune checkpoint inhibitors (ICIs). There was significantly higher CHST12 mRNA expression in PAAD samples than in non-malignant samples.ConclusionsIn PAAD, elevated CHST12 mRNA expression might regulate immune cell infiltration into the tumor microenvironment (TME) and may predict clinical outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma

Liu,

Li,

Han

2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer (CRC) ranks third globally in terms of cancer incidence (10.0%), and second in terms of mortality (9.4%)[ 1 ]. Advanced CRC readily metastasizes to the liver, lungs, bones, brain, and even pancreas[ 2 ] and spleen[ 3 ], significantly impacting patient prognosis. Hence, early screening for CRC and even intercepting it in the precancerous state are crucial for reducing the incidence and mortality rates of CRC.…”

Section: Introductionmentioning

confidence: 99%

Screening of colorectal cancer: Methods and strategies

Liao,

Guo,

Yang

et al. 2024

World J Clin Oncol

View full text Add to dashboard Cite

Colorectal cancer (CRC) has high incidence and mortality rates, and the emergence and application of CRC screening have helped us effectively control the occurrence and development of CRC. Currently, common international screening methods include tests based on feces and blood, and examination methods that allow for visualization, such as sigmoidoscopy and colonoscopy. Some methods have been widely used, whereas others such as multi-target stool RNA test are still being explored and developed, and are expected to become front-line screening methods for CRC in the future. The choice of screening method is affected by external conditions and the patients' situation, and the clinician must choose an appropriate strategy according to the actual situation and the patient's wishes. This article introduces various CRC screening methods and analyzes the factors relevant to the screening strategy.

show abstract

A pancreatic metastasis from a colon carcinoma mimicking a primary tumor diagnosed by EUS-guided fine-needle biopsy

Cited by 2 publications

References 6 publications

CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma

CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma

Screening of colorectal cancer: Methods and strategies

Contact Info

Product

Resources

About